Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19Review Published on 2021-09-232022-10-28 Journal: Pharmaceuticals [Category] COVID-19, [키워드] Adverse adverse event adverse events alteration approved authorization Baricitinib Biological agent Case report clinical trial common adverse event COVID-19 drug drug interaction effective drug Emergency hospitalized patients immune dysregulation Infection Inflammatory inhibit kidneys Liver function mechanism metabolic pathway moderate-to-severe COVID-19 MONITOR monoclonal antibody pathogenic pathway Patient Pharmacology Remdesivir reported risk risk factor sarilumab Serious Adverse Event Surveillance Thromboembolism Tocilizumab Toxicity Treatment Treatment strategies [DOI] 10.3390/ph14100955 PMC 바로가기 [Article Type] Review
Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?COVID-19 발생 시 류마티스 질환에 대한 생물학적 제제: 친구 또는 적?Observational Study Published on 2021-01-012022-09-12 Journal: RMD Open [Category] 임상, 진단, [키워드] affected age analysed Autoimmunity Baricitinib Biological agent biological therapy cardiovascular disease Care Community Comorbidities covariate COVID-19 COVID-19 infection cytokine production determine diagnosed diagnosed with COVID-19 Diagnosis disease dose drug Epidemiology epidemiology. exacerbated form General population glucocorticoid group hospital Hospital admission hospitalisation hypertension IL-1 IL-6 IL-6 inhibitor IL-6 inhibitors immunosuppressed patient incidence of COVID-19 incidence rate Inflammation Inflammatory inhibitor inhibitors intensive care IQR JAK inhibitor less lowest management manifestation median age multivariate logistic regression no difference no significant difference occur Older outbreak outpatient clinic Patient patients patients died patients treated patients with COVID-19 performed positive prognosis of patient proportions Protective protective effect protective factor raised receiving required retrospective rheumatic disease Rheumatic diseases rheumatological rheumatology risk risk factor sarilumab SARS-CoV-2 severe COVID-19 disease Sex smoker Spain suggested tested therapy Tocilizumab Treatment with COVID-19 [DOI] 10.1136/rmdopen-2020-001439 PMC 바로가기 [Article Type] Observational Study
Evidence for systematic autopsies in COVID-19 positive deceased Case report of the first German investigated COVID-19 deathCase Reports Published on 2020-05-252022-10-28 Journal: Rechtsmedizin (Berlin, Germany) [Category] COVID-19, [키워드] acute respiratory syndrome agent Autopsies Autopsy Biological Biological agent Biological Agents Ordinance Biostoffverordnung category Cell Computed tomography consolidation coronavirus Course COVID-19 death Deceased Diseases Forensic medicine Health health worker high risk autopsy Hochrisiko-Autopsie Human illness investigated lung tissue measure microorganisms parasites pathogen pathology pharyngeal mucosa positive Post-mortem Robert Koch SARS-CoV-2 SARS-CoV‑2 SARS-CoV‑2 infection SARS-CoV‑2 Spread Verstorbene Viral pneumonia Viral RNA [DOI] 10.1007/s00194-020-00401-4 PMC 바로가기 [Article Type] Case Reports